ClinicalTrials.gg
CompletedNCT07889778LCSAUpdated Oct 22, 2026

Learning to Communicate Successfully Approach for Urdu Speaking Patients With Chronic Aphasia

An interventional study of Learning to Communicate Successfully Approach (LCSA) in Aphasia, sponsored by University of Lahore. Completed at 2 sites in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University of Lahore · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jul 2025, registered Oct 2026).
Updated Oct 22, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to develop and validate the Learning to Communicate Successfully Approach (LCSA), a culturally sensitive communication intervention manual for Urdu-speaking adults with chronic aphasia. Aphasia is a language disorder that can affect speaking, understanding, reading, writing, and everyday communication, commonly following stroke or other neurological conditions. The LCSA addresses communication difficulties while also considering participation in daily life, communication partners, the communication environment, and personal and psychosocial factors. The study evaluates the feasibility, applicability, and outcomes of the LCSA approach in Urdu-speaking adults with chronic aphasia.

Read the detailed description

Aphasia is an acquired language disorder that can affect an individual's ability to speak, understand spoken language, read, and write. People living with chronic aphasia may experience persistent communication difficulties that affect participation in everyday activities, relationships, and quality of life.

This study aims to develop and validate the Learning to Communicate Successfully Approach (LCSA) manual for Urdu-speaking adults with chronic aphasia. The LCSA is a culturally sensitive, comprehensive intervention approach that addresses communication difficulties from multiple perspectives. The approach incorporates impairment-based intervention, participation-focused intervention, communication partner training, communication environment modification, and personal and psychosocial factors.

The LCSA manual's development included a qualitative phase with input from speech-language pathologists and caregivers, followed by expert review and face-validity assessment. The team then implemented the manual with Urdu-speaking adults with chronic aphasia to evaluate its applicability and outcomes.

The quantitative phase uses a one-group pre-test-post-test design to evaluate changes in communication and related functional outcomes following implementation of the LCSA. Participants undergo assessment before and after the intervention using standardized and study-related outcome measures. The findings are intended to provide evidence regarding the validity, applicability, and potential effectiveness of the LCSA manual for Urdu-speaking adults with chronic aphasia.

The study is intended to contribute to culturally and linguistically appropriate aphasia rehabilitation by providing speech-language pathologists with a structured intervention approach specifically developed for Urdu-speaking individuals with chronic aphasia.

02

Conditions studied

  • Aphasia

Keywords

  • Aphasia
  • Rehabilitation
  • Speech-Language Pathology
  • Communication
  • Neurological Rehabilitation
  • Learning to Communicate Successfully Approach
  • LCSA
03

In context

Aphasia

372 studies on the registry are indexed under Aphasia; 90 are open to participants now.

This study's enrollment of 30 is close to the median of 30 across 322 interventional studies indexed under Aphasia.

Browse Aphasia studies →

Lead sponsor

University of Lahore is the lead sponsor of 230 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male and female patients
  • Mild or moderate level on the Glasgow Coma Scale (GCS)
  • Diagnosed with chronic aphasia
  • Passed hearing and vision screening

Exclusion criteria

Exclusion Criteria:

  • Patients with impaired levels of consciousness
  • Patients speaking a language other than Urdu in the acute stage
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Learning to Communicate Successfully Approach (LCSA)

    Participants with chronic aphasia receive the Learning to Communicate Successfully Approach (LCSA), a structured, culturally sensitive communication intervention designed to address communication impairment, participation in everyday communication, communication partner involvement, the communication environment, and personal and psychosocial factors. Assess outcomes before and after the intervention.

    Behavioral: Learning to Communicate Successfully Approach (LCSA)

Interventions

  • BehavioralLearning to Communicate Successfully Approach (LCSA)

    The Learning to Communicate Successfully Approach (LCSA) is a structured, culturally sensitive communication intervention developed for Urdu-speaking adults with chronic aphasia. The approach integrates impairment-based intervention, participation-focused intervention, communication partner training, communication environment modification, and personal and psychosocial support. A speech-language pathologist delivers the intervention according to the LCSA manual.

06

What researchers measure

Primary outcomes

  1. Aphasia Severity and Language Function

    We assessed aphasia severity and language function using the Quick Aphasia Battery (QAB).

    Time frame: Baseline and immediately after completion of the intervention.

Secondary outcomes

  1. Impact of Aphasia on Quality of Life

    The impact of aphasia on quality of life and participation was assessed using the Aphasia Impact Questionnaire-21 (AIQ-21).

    Time frame: Baseline and immediately after completion of the intervention.

07

Study locations

2 sites
  • University of Lahore Teaching Hospital
    Lahore, Punjab Province 54792, Pakistan
  • Combined Military Hospital (CMH), Lahore, Pakistan
    Lahore, Punjab Province 54800, Pakistan
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share individual participant data with other researchers. The research team will retain participant-level data and handle it confidentially in accordance with the approved research ethics requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Mar 2026, 7 months.

Of 197 non-industry interventional studies with no phase under Aphasia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 7 months is below that.

Counting every sponsor, half of 200 studies reached it within 36 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2026
First posted
Oct 22, 2026
StartActual
Jul 17, 2025
Primary completionActual
Mar 10, 2026
CompletionActual
Mar 10, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07889778
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Jul 17, 2025
Primary completion
Mar 10, 2026
Completion
Mar 10, 2026
Last update
Oct 22, 2026

Study contacts

Abdoul Aziz Fall, PhD
principal investigator · University of Cyberjaya
MUHAMMAD AHMED, PhD Medical Sciences
principal investigator · University of Cyberjaya

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion